0001213900-23-018553.txt : 20230308 0001213900-23-018553.hdr.sgml : 20230308 20230308161646 ACCESSION NUMBER: 0001213900-23-018553 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230308 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230308 DATE AS OF CHANGE: 20230308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OptimizeRx Corp CENTRAL INDEX KEY: 0001448431 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 261265381 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38543 FILM NUMBER: 23716334 BUSINESS ADDRESS: STREET 1: 400 WATER ST., STE. 200 CITY: ROCHESTER STATE: MI ZIP: 48307 BUSINESS PHONE: 248-651-6558 MAIL ADDRESS: STREET 1: 400 WATER ST., STE. 200 CITY: ROCHESTER STATE: MI ZIP: 48307 8-K 1 ea174846-8k_optimizerx.htm CURRENT REPORT
0001448431 false 0001448431 2023-03-08 2023-03-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): March 8, 2023

 

OptimizeRx Corporation

(Exact name of registrant as specified in charter)

 

Nevada   001-38543   26-1265381
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

400 Water Street, Suite 200, Rochester, MI   48307
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 248.651.6568

 

Not Applicable 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 Par Value   OPRX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 8, 2023, OptimizeRx Corporation issued a press release announcing preliminary financial results for the fourth quarter and year ended December 31, 2022, providing Key Performance Indicators and initial 2023 guidance. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

 

The information in this Item 2.02 and Exhibit 99.1 attached hereto are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit
Number		   Description
99.1   Press Release, dated March 8, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  OPTIMIZERX CORPORATION
     
Date: March 8, 2023 By: /s/ Edward Stelmakh
  Name:  Edward Stelmakh
  Title: Chief Financial Officer

 

 

2

 

 

 EX-99.1 2 ea174846ex99-1_optimizerx.htm PRESS RELEASE, DATED MARCH 8, 2023

Exhibit 99.1

 

OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results

 

-Q4 revenue of $19.7 million, down 3% year-over-year and up 30% quarter-over-quarter

 

-Q4 gross profit increased 1% year-over-year to $12.5 million as gross margins increased from 61% to 63%

 

-Generated $10.7 million in cash flow from operations in 2022

 

-Repurchased 1.2 million shares during 2022 at an average price of $16.49 per share

 

-Exited 2022 with six Real-World Data Artificial Intelligence (RWD-AI) deals

 

ROCHESTER, Mich. – March 8, 2023 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the fourth quarter and full year ended December 31, 2022.

 

   Twelve Months Ended
December 31,		 
Key Performance Indicators (KPIs)*  2022   2021 
Average revenue per top 20 pharmaceutical manufacturer  $2,143,296   $2,484,557 
Percent of top 20 pharmaceutical manufacturers that are customers   90%   95%
Percent of total revenue attributable to top 20 pharmaceutical manufacturers   62%   77%
Net revenue retention   90%   127%
Revenue per average full-time employee  $606,312   $729,674 

 

Will Febbo, OptimizeRx CEO commented, “Macro headwinds made 2022 an extremely challenging year. As a result, we are taking a conservative approach to guidance for 2023. However, during 2022, we made the decision to skate to where the puck is going to be and strengthened our platform and team around advanced/smarter solutions, particularly our RWD-AI offering. We believe this is bearing fruit, which is best evidenced by our exiting 2022 with six RWD-AI deals. Even more encouraging is the RWD-AI pipeline that's been built in recent months, which now encompasses several dozen deals. I believe our current revenue backlog, and the momentum we are currently seeing, positions the Company to return to at least double digit revenue growth this year.

 

"We continue to be at the nexus of a paradigm shift in health technology enablement. The culmination of our technology investments, partnerships and acquisitions in combination with the largest in workflow point of care network in the U.S., has created a robust single stop, total solution suite that is delivering care focused engagement between life science organizations, doctors and patients while driving a superior ROI for the brands that we serve. Looking ahead, we see our land and expand strategy continue to capture industry whitespace over the next three to five years which we believe will result in the Company growing to multiples of its current size."

 

 

 

 

Financial Highlights

 

●Revenue in the fourth quarter of 2022 decreased 3% to $19.7 million, from $20.3 million in the same period of 2021, with the full year of 2022 up 2% as compared to the same year-ago period.

 

●Gross profit in the fourth quarter of 2022 increased 1% year-over-year to $12.5 million.

 

●GAAP net loss totaled $(0.3) million or $(0.02) per basic and diluted share in the fourth quarter.

 

●Non-GAAP net income in the fourth quarter totaled $4.4 million or $0.25 per fully diluted shares outstanding. (see definition of this non-GAAP measure and reconciliation to GAAP, below).

 

●Completed our 2022 share repurchase program and repurchased 1,214,398 shares during 2022 at an average price of $16.49 per share

 

●Cash, cash equivalents and short-term investments totaled $74.1 million as of December 31, 2022, as compared to $78.8 million as of September 30, 2022.

 

Financial Outlook

 

For the full year 2023, the Company expects net revenues to increase at least 10% year-over-year, and gross margins to be between 58% and 62%.

 

OptimizeRx is providing revenue guidance for its fiscal first quarter ending March 31, 2023 and is looking for revenue to come in between $11.5 million and $13 million.

 

Conference Call

 

OptimizeRx management will host the presentation, followed by a question-and-answer period.

 

Date: Wednesday, March 8, 2023

Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)

Web access: https://viavid.webcasts.com/starthere.jsp?ei=1600324&tp_key=1bf1fbca3f

Toll-free dial-in number: 1-888-886-7786

International dial-in number: 1-416-764-8658

Conference ID: 26399560

 

Please call the conference telephone number five minutes prior to the start time.

 

A replay of the call will remain available for 12 months via the Investors section of the OptimizeRx website at www.optimizerx.com/investors.

 

2

 

 

Definition and Use of Non-GAAP Financial Measures

 

This earnings release includes a presentation of non-GAAP net income and non-GAAP net income per diluted share or non-GAAP EPS, both of which are non-GAAP financial measures.

 

The Company defines non-GAAP net income as GAAP net income (loss) with an adjustment to add back depreciation, amortization, stock-based compensation, acquisition expenses, income or loss related to the fair value of contingent consideration, and deferred income taxes. Non-GAAP EPS is defined as non-GAAP net income (loss) divided by the number of weighted average shares outstanding on a diluted basis. The Company has provided non-GAAP financial measures to aid investors in better understanding its performance. Management believes that these non-GAAP financial measures provide additional insight into the operations and cash flow of the Company.

 

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a Company’s non-cash operating expenses, management believes that providing non-GAAP financial measures that exclude non-cash expenses allows for meaningful comparisons between the Company’s core business operating results and those of other companies, as well as provides an important tool for financial and operational decision making and for evaluating the Company’s own core business operating results over different periods of time.

 

The Company’s non-GAAP net income and non-GAAP EPS measures may not provide information that is directly comparable to that provided by other companies in the Company’s industry, as other companies in the industry may calculate such non-GAAP financial results differently. The Company’s non-GAAP net income and non-GAAP EPS are not measurements of financial performance under GAAP and should not be considered as an alternative to operating income or as an indication of operating performance or any other measure of performance derived in accordance with GAAP. The Company does not consider these non-GAAP measures to be substitutes for or superior to the information provided by its GAAP financial results.

 

The table, “Reconciliation of Non-GAAP to GAAP Financial Measures,” included below, provides a reconciliation of Non-GAAP net income and Non-GAAP EPS for the fourth quarter and full year ended December 31, 2022 and 2021.

 

Definition of Key Performance Indicators*

 

Top 20 pharmaceutical manufacturers: Top 20 pharmaceutical manufacturers are based on Fierce Pharma’s “The top 20 pharma companies by 2020 revenue.”

 

Net revenue retention: Net revenue retention is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year).

 

Revenue per average Full Time Employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount at the end of the most recent period.

 

About OptimizeRx

 

OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on their medications. 

 

For more information, follow the Company on Twitter, LinkedIn or visit www.optimizerx.com. 

 

3

 

 

Important Cautions Regarding Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.

 

OptimizeRx Contact

 

Andy D’Silva, SVP Corporate Finance

adsilva@optimizerx.com

 

Investor Relations Contact

 

Ashley Robinson

LifeSci Advisors, LLC

arr@lifesciadvisors.com

 

 

4

 

 

OPTIMIZERx CORPORATION

CONSOLIDATED BALANCE SHEETS

 

   December 31,
2022		   December 31,
2021		 
         
ASSETS        
Current Assets        
Cash and cash equivalents  $18,208,685   $84,681,770 
Short-term investments   55,931,821    — 
Accounts receivable, net   22,155,301    24,800,585 
Prepaid expenses and other   2,280,828    5,630,655 
Total Current Assets   98,576,635    115,113,010 
Property and equipment, net   137,448    143,818 
Other Assets          
Goodwill   22,673,820    14,740,031 
Technology assets, net   7,702,895    4,589,126 
Patent rights, net   1,940,178    2,155,026 
Right of use assets, net   235,320    328,820 
Other intangible assets, net   3,379,838    3,902,502 
Security deposits and other assets   5,051    12,859 
Total Other Assets   35,937,102    25,728,364 
TOTAL ASSETS  $134,651,185   $140,985,192 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current Liabilities          
Accounts payable – trade  $1,549,979   $606,808 
Accrued expenses   2,601,246    2,902,836 
Revenue share payable   3,990,440    4,378,216 
Current portion of lease liabilities   89,902    90,982 
Deferred revenue   164,309    1,389,907 
Total Current Liabilities   8,395,876    9,368,749 
Non-Current Liabilities          
Lease liabilities, net of current portion   144,532    236,726 
Total Liabilities   8,540,408    9,605,475 
Commitments and contingencies (See Note 15)          
Stockholders’ Equity          
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2022 and 2021, respectively   —    — 
Common stock, $0.001 par value, 166,666,667 shares authorized, 18,288,571 and 17,860,975 shares issued at December 31, 2022 and 2021, respectively   18,289    17,861 
Treasury stock, $0.001 par value, 1,214,398 and none purchased at December 31, 2022 and 2021, respectively   (1,214)   — 
Additional paid-in-capital   172,785,800    166,615,514 
Accumulated deficit   (46,692,098)   (35,253,658)
Total Stockholders’ Equity  $126,110,777   $131,379,717 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $134,651,185   $140,985,192 

 

The accompanying notes are an integral part of these financial statements.

 

5

 

 

OPTIMIZERx CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   For the year ended
December 31,		   For the year ended
December 31,		 
   2022   2021 
         
Net revenue  $62,450,156   $61,292,598 
Cost of revenues   23,483,336    25,654,384 
Gross margin   38,966,820    35,638,214 
           
Operating Expenses          
Stock-based compensation   15,745,822    5,491,957 
Depreciation, amortization, and noncash lease expense   2,022,029    2,086,454 
Other general and administrative expenses   33,489,707    27,698,703 
Total operating expenses   51,257,558    35,277,114 
Income (loss) from operations   (12,290,738)   361,100 
Other income          
Interest income   852,298    16,979 
Income (loss) before provision for income taxes   (11,438,440)   378,079 
Income tax benefit   —    — 
Net income (loss)  $(11,438,440)  $378,079 
Weighted average number of shares outstanding – basic   17,783,992    17,228,019 
Weighted average number of shares outstanding – diluted   17,783,992    17,690,489 
Income (loss) per share – basic  $(0.64)  $0.02 
Income (loss) per share – diluted  $(0.64)  $0.02 

 

The accompanying notes are an integral part of these financial statements.

 

6

 

 

OPTIMIZERx CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   For the year ended
December 31,		 
   2022   2021 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net (loss) income  $

(11,438,440

)  $378,079 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:          
Depreciation and amortization   2,022,029    1,965,325 
Increase in bad debt reserve   363,512    80,000 
Stock-based compensation   15,745,822    5,491,957 
Changes in:          
Accounts receivable   2,281,773    (6,994,880)
Prepaid expenses and other assets   2,650,951    (1,174,044)
Accounts payable   943,171    (11,442)
Revenue share payable   (387,776)   (591,652)
Accrued expenses and other liabilities   (301,592)   482,475 
Change in operating lease liabilities   226    (3,891)
Deferred revenue   (1,225,598)   1,104,112 
NET CASH PROVIDED BY OPERATING ACTIVITIES   10,654,078    726,039 
           
CASH FLOWS USED IN INVESTING ACTIVITIES:          
Purchases of property and equipment   (81,005)   (100,322)
EvinceMed acquisition   (2,000,000)   — 
Purchase of short-term investments   (55,931,821)   — 
Acquisition of intangible assets, including intellectual property rights   (1,830)   (21,511)
Capitalized software development costs   (161,730)   (364,166)
NET CASH USED IN INVESTING ACTIVITIES   (58,176,386)   (485,999)
           
CASH FLOWS (USED IN ) / PROVIDED BY FINANCING ACTIVITIES:          
Proceeds from public offering of common stock, net of offering costs   —    70,671,536 
Repurchase of common stock   (20,024,258)   — 
Proceeds from exercise of stock options, net of cash paid for withholding taxes   1,073,481    4,864,231 
Payment of contingent consideration   —    (1,610,813)
NET CASH (USED IN) / PROVIDED BY FINANCING ACTIVITIES   (18,950,777)   73,924,954 
NET (DECREASE) /  INCREASE IN CASH AND CASH EQUIVALENTS   (66,473,085)   74,164,994 
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD   84,681,770    10,516,776 
CASH AND CASH EQUIVALENTS – END OF PERIOD  $18,208,685   $84,681,770 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
Cash paid for interest  $—   $— 
Reduction of EvinceMed purchase price for amounts previously paid  $708,334   $— 
Shares issued in connection with acquisition  $9,374,455   $— 
Cash paid for income taxes  $—   $— 

 

The accompanying notes are an integral part of these financial statements.

 

7

 

 

OPTIMIZERx CORPORATION

RECONCILIATION of NON-GAAP to GAAP FINANCIAL MEASURES

 

   For the Three Months
Ended
December 31,		   For the Twelve Months
Ended
December 31,		 
   2022   2021   2022   2021 
Net (Loss) Income  $(325,836)  $623,462   $(11,438,440)  $378,079 
Depreciation and amortization   456,545    506,279    2,022,029    2,086,452 
Stock-based compensation   4,269,160    2,879,759    15,745,822    5,491,957 
Acquisition expense   —    —    19,739    — 
Non-GAAP net income   4,399,869    4,009,500    6,349,150    7,956,488 
                     
Non-GAAP net income per share                    
Diluted  $0.25   $0.22   $0.35   $0.45 
Weighted average shares outstanding:                    
Diluted   17,285,777    18,410,160    18,048,477    17,690,489 

 

 

8

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 oprx-20230308.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 oprx-20230308_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 oprx-20230308_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Mar. 08, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 08, 2023
Entity File Number 001-38543
Entity Registrant Name OptimizeRx Corporation
Entity Central Index Key 0001448431
Entity Tax Identification Number 26-1265381
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 400 Water Street
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Rochester
Entity Address, State or Province MI
Entity Address, Postal Zip Code 48307
City Area Code 248
Local Phone Number 651.6568
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value
Trading Symbol OPRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

XML 8 ea174846-8k_optimizerx_htm.xml IDEA: XBRL DOCUMENT 0001448431 2023-03-08 2023-03-08 iso4217:USD shares iso4217:USD shares 0001448431 false 8-K 2023-03-08 OptimizeRx Corporation NV 001-38543 26-1265381 400 Water Street Suite 200 Rochester MI 48307 248 651.6568 false false false false Common Stock, $0.001 Par Value OPRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://optimizerx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea174846-8k_optimizerx.htm ea174846ex99-1_optimizerx.htm oprx-20230308.xsd oprx-20230308_lab.xml oprx-20230308_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea174846-8k_optimizerx.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea174846-8k_optimizerx.htm" ] }, "labelLink": { "local": [ "oprx-20230308_lab.xml" ] }, "presentationLink": { "local": [ "oprx-20230308_pre.xml" ] }, "schema": { "local": [ "oprx-20230308.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "OPRX", "nsuri": "http://optimizerx.com/20230308", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea174846-8k_optimizerx.htm", "contextRef": "From2023-03-08to2023-03-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://optimizerx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea174846-8k_optimizerx.htm", "contextRef": "From2023-03-08to2023-03-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://optimizerx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001213900-23-018553-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-018553-xbrl.zip M4$L#!!0 ( !:":%94XHA2:1( $)C : 96$Q-S0X-#8M.&M?;W!T M:6UI>F5R>"YH=&WM/&USVKK2WS.3_Z#+>7HGG1O &$* )-PA0%*:!"B0)CE? M,L(6H,;8CF3STE]_5[(-!@QY*6G:TZ?M%+"D?=/N:G.! _V@K\E/8@/'L0O)Y'@\3HS3"8OU MDZE\/I^#UF R;K M^J8$S< AN3UM7FM!9M-0FO0T>7Q M/L;VK',/\Z[LZ#]+-NA0_J=L$E"LX:B7UI) M*[F8-&F"=?A$XL^Q0QV#%(^3WB>T#HF#D8 2)X\N'9W$RI;I@"SBG:D-//'9VNW MF[Q>9O ^8? &D3'8VZC7##Y1[ EH-',"_ MJ@DRG)9!. P;-5,GDPLRO5? \V4RN4PZ]1*X^1#<$FBB+K3QS,#]^QXV.'D! MJ*R0=.4^=>\[) \F/'H)#/6^/<",\'OU7OI?#PB7SUX"IR)H:?JPTBLDK07> MM?0IXL[4(">Q'BA@ :44VT$=.H0N=3)&+6N(S7WOP3X0P&A/JKI.1\$XG7+; MP-,",BV3R$8Z*0B=)4P8@_Q%=9V8TC3$3^A8=X< 2_.T?N*TA,@T$(+D(%P;29ULVF\0#W9T]ESJHN6'B4,259(Y&)8KETL MSLSRX#FZ9"0^'YL-\K7T52H@(F%.!3ND.&4R6*8Q"FH(:868UI":3Z%]6B[+>*, !^T+ M4E@1J&^A(7OTW$/@&X^3,!X^Q=]C^Z5^^ @-,>M3LX!$5^4("66,8X/VX9$& MAD18#.(/6R((+R,MUR#Q)N[+U2[LR3UX<<>R)

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